Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Change in Inventory (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Change in Inventory for 14 consecutive years, with -$135000.0 as the latest value for Q4 2025.

  • Quarterly Change in Inventory fell 4400.0% to -$135000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$185000.0 through Dec 2025, down 18600.0% year-over-year, with the annual reading at -$185000.0 for FY2025, 18600.0% down from the prior year.
  • Change in Inventory hit -$135000.0 in Q4 2025 for Guided Therapeutics, down from -$12000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $74000.0 in Q3 2023 to a low of -$135000.0 in Q4 2025.
  • Historically, Change in Inventory has averaged -$4411.8 across 5 years, with a median of -$1000.0 in 2021.
  • Biggest five-year swings in Change in Inventory: skyrocketed 6000.0% in 2023 and later tumbled 4400.0% in 2025.
  • Year by year, Change in Inventory stood at -$47000.0 in 2021, then soared by 170.21% to $33000.0 in 2022, then plummeted by 145.45% to -$15000.0 in 2023, then soared by 80.0% to -$3000.0 in 2024, then crashed by 4400.0% to -$135000.0 in 2025.
  • Business Quant data shows Change in Inventory for GTHP at -$135000.0 in Q4 2025, -$12000.0 in Q3 2025, and -$38000.0 in Q2 2025.